Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (S-1+Oxaliplatin) and radiotherapy for locally advanced esophagogastric junction adenocarcinoma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06250894
Study type Interventional
Source Wuhan Union Hospital, China
Contact
Status Recruiting
Phase Phase 2
Start date March 30, 2021
Completion date March 30, 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT01747707 - Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer Phase 2
Active, not recruiting NCT03221426 - Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Phase 3
Completed NCT02178956 - A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Phase 3
Active, not recruiting NCT02872116 - Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Phase 3
Completed NCT02538562 - Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea N/A
Recruiting NCT05322577 - A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. Phase 1
Terminated NCT01813253 - Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer Phase 3
Recruiting NCT06346392 - AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 Phase 3
Active, not recruiting NCT04276493 - Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab Phase 1/Phase 2
Terminated NCT02726399 - Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer Phase 2
Recruiting NCT05395780 - A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer Phase 2
Completed NCT02581462 - FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer Phase 2/Phase 3
Completed NCT02661971 - FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) Phase 2/Phase 3
Completed NCT00917462 - Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer Phase 2
Recruiting NCT05187182 - CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer Phase 1
Not yet recruiting NCT06411171 - Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer: Phase 3
Completed NCT03529266 - Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcinoma. Phase 2